Current experimental therapy for Alzheimer's disease

被引:13
作者
Chen, Sheng
Zhang, Xiao-Jie
Li, Liang
Le, Wei-Dong [1 ]
机构
[1] Shanghai Jiao Tong Univ, Ruijin Hosp, Inst Neurol, Shanghai 200030, Peoples R China
[2] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, Lab Neurogenom, Beijing 100864, Peoples R China
关键词
experimental approach; Alzheimer's disease; secretase; amyloid plaque; neurofibrillary tangles; immunotherapy; small interfering molecule; gene therapy;
D O I
10.2174/157015907780866901
中图分类号
Q189 [神经科学];
学科分类号
071006 [神经生物学];
摘要
In the past decade, enormous efforts have been devoted to understand the genetics and molecular pathogenesis of Alzheimer's disease (AD), which has been transferred into extensive experimental approaches aimed at reversing disease progression, The trend in future AD therapy has been shifted from traditional anti-acetylcholinesterase treatment to multiple mechanisms-based therapy targeting anlyloid plaques formation and amyloid peptides (A beta)-mediated cytotoxicity, and neurofibrillary tangles generation. This review will cover current experimental studies with the focus on secretases-based drug development, immunotherapy, and anti-neurofibrillary tangles intervention. The outcome of these on-going studies may provide high hope that AD can be cured in the future.
引用
收藏
页码:127 / 134
页数:8
相关论文
共 97 条
[1]
Pharmacological profiles of peptide drug candidates for the treatment of Alzheimer's disease [J].
Adessi, C ;
Frossard, MJ ;
Boissard, C ;
Fraga, S ;
Bieler, S ;
Ruckle, T ;
Vilbois, F ;
Robinson, SM ;
Mutter, M ;
Banks, WA ;
Soto, C .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (16) :13905-13911
[2]
Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease [J].
Adlard, PA ;
Perreau, VM ;
Pop, V ;
Cotman, CW .
JOURNAL OF NEUROSCIENCE, 2005, 25 (17) :4217-4221
[3]
Agdeppa Eric D, 2003, Mol Imaging Biol, V5, P404, DOI 10.1016/j.mibio.2003.09.010
[4]
Protein synthesis required for long-term memory is induced by PKC activation on days before associative learning [J].
Alkon, DL ;
Epstein, H ;
Kuzirian, A ;
Bennett, MC ;
Nelson, TJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (45) :16432-16437
[5]
Reductions in β-amyloid concentrations in vivo by the γ-secretase inhibitors BMS-289948 and BMS-299897 [J].
Anderson, JJ ;
Holtz, G ;
Baskin, PP ;
Turner, M ;
Rowe, B ;
Wang, BW ;
Kounnas, MZ ;
Lamb, BT ;
Barten, D ;
Felsenstein, K ;
McDonald, I ;
Srinivasan, K ;
Munoz, B ;
Wagner, SL .
BIOCHEMICAL PHARMACOLOGY, 2005, 69 (04) :689-698
[6]
Appel SH, 1996, ADV NEUROL, V69, P153
[7]
Inhibition of amyloid precursor protein processing by β-secretase through site-directed antibodies [J].
Arbel, M ;
Yacoby, I ;
Solomon, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (21) :7718-7723
[8]
Arenas E, 1996, MOL PSYCHIATR, V1, P179
[9]
Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease [J].
Bard, F ;
Cannon, C ;
Barbour, R ;
Burke, RL ;
Games, D ;
Grajeda, H ;
Guido, T ;
Hu, K ;
Huang, JP ;
Johnson-Wood, K ;
Khan, K ;
Kholodenko, D ;
Lee, M ;
Lieberburg, I ;
Motter, R ;
Nguyen, M ;
Soriano, F ;
Vasquez, N ;
Weiss, K ;
Welch, B ;
Seubert, P ;
Schenk, D ;
Yednock, T .
NATURE MEDICINE, 2000, 6 (08) :916-919
[10]
Dynamics of β-amyloid reductions in brain, cerebrospinal fluid, and plasma of β-amyloid precursor protein transgenic mice treated with a γ-secretase inhibitor [J].
Barten, DM ;
Guss, VL ;
Corsa, JA ;
Loo, A ;
Hansel, SB ;
Zheng, M ;
Munoz, B ;
Srinivasan, K ;
Wang, B ;
Robertson, BJ ;
Polson, CT ;
Wang, J ;
Roberts, SB ;
Hendrick, JP ;
Anderson, JJ ;
Loy, JK ;
Denton, R ;
Verdoorn, TA ;
Smith, DW ;
Felsenstein, KM .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 312 (02) :635-643